NBP is a Class 1 new chemical drug in China and a patent-protected exclusive product mainly used for the treatment of acute ischemic stroke. It is recommended in the guidelines of various professional organisations such as the Chinese Medical Association and the Chinese Stroke Association for the treatment of acute ischemic stroke, and is also listed in more than twenty domestic authoritative clinical guidelines and expert consensuses. The new NRDL negotiated price implemented in March 2021 has significantly improved product accessibility and resulted in rapid sales volume growth. In respect of the development of new therapeutic areas, there are currently more than 180 research projects in progress. In particular, the overall progress of the clinical trials for the treatment of vascular dementia is smooth with patient enrolment under way, and the enrolment for four of the six 13th Five-Year Plan studies have completed with results expected to come out in 2022.

Conjupri is mainly used for the treatment of hypertension, chronic stable angina and variant angina, and is a product in the NRDL and essential drug list. It is listed in the Guidelines for the Prevention and Treatment of Hypertension in China, Guidelines for the Rational Use of Drugs in Hypertension and other authoritative guidelines in China, and is the first Chinese innovative drug granted full approval by the FDA.

Jinyouli is the first long-acting white blood cell booster drug developed in China. It is used to prevent and treat incidence of infection and pyrexia due to low neutrophil count in patients receiving chemotherapy, thus ensuring the administration of standardised dosage of chemotherapy. Jinyouli is well supported by clinical evidence, earning unanimous recommendations in domestic and foreign guidelines. The Group is further expanding its use into areas including gastrointestinal tumours, head and neck cancer, childhood acute lymphoblastic leukemia, as well as expanding its coverage in core hospitals in cities and in county-level markets.

Duomeisu is a product developed by the National Key Laboratory for New Pharmaceutical Preparations and Excipients of the Group and supported by the Major New Drug Development project in China. It is recommended by the U.S. National Comprehensive Cancer Network (NCCN) Guidelines and the Chinese Society of Clinical Oncology (CSCO) for the first-line treatment of lymphoma, ovarian cancer, relapsed or metastatic breast cancer, soft tissue sarcoma and AIDS-related Kaposi’s sarcoma. In May 2021, Duomeisu passed the consistency evaluation, further enhancing the brand’s advantages and providing a strong foundation for the expansion of its market share.

Keaili is the first-to-market generic of new generation paclitaxel chemotherapy drug in China with the consistency evaluation passed. The drug has the distinctive features of convenience, high efficacy and safety. It has been unanimously recommended by domestic and foreign guidelines and expert consensus for breast cancer, lung cancer, gastric cancer and gynaecological tumours. Following the price reduction of 70% in 2020 and inclusion into the NRDL in 2021, the financial burden of patients has been greatly reduced and accessibility of the drug significantly enhanced, leading to substantial growth of the product. The Group will continue to capitalise on the policies to accelerate hospital access and market penetration in order to increase market share, and further expand into new areas such as gastric cancer, esophageal cancer, head and neck cancer, pancreatic cancer and melanoma while consolidating core areas in breast cancer, lung cancer and gynaecological tumours.

Duoenda, a new and upgraded mitoxantrone liposome product, is a new class 2 drug developed by the Group with patents in several countries. By encapsulating in liposome, the pharmacokinetics and tissue distribution of mitoxantrone in vivo were altered, therefore reducing cardiotoxicity and other non-haematological toxicity, and effectively reducing common adverse reactions of liposomes such as infusion-related reactions, handfoot syndrome and skin mucosal toxicity; allowing for higher dose, achieving higher anti-tumor activity and longer-lasting relief for diseases; achieving precision in tumor targeting; prolonging the intracorporeal circulation of the drug and improving the resistance of NK/T-cell lymphoma therapies to conventional anthracycline drugs, offering a new option for the treatment of relapsed/refractory peripheral T-cell lymphoma (PTCL). Mitoxantrone has a broad spectrum of anti-tumor activity with major indications including malignant lymphoma, breast cancer and acute leukaemia, and has also shown efficacy in lung cancer, ovarian cancer, melanoma and multiple myeloma. The Group is also actively exploring the clinical development of Duoenda in haematological tumors such as leukaemia and multiple myeloma, as well as solid tumours such as head and neck tumours and ovarian cancer. Duoenda was granted drug registration approval in January 2022 for the treatment of relapsed or refractory peripheral T-cell lymphoma and was launched to market in February.

Anfulike was granted drug registration approval with priority review in March 2021. It is recommended jointly by the State Ministry of Industry and Health Care Commission as a “clinically urgent, market deficient” product. Anfulike is indicated for the treatment of patients with invasive fungal infections, patients with renal impairment or drug toxicity precludes the use of effective dose of amphotericin B, or patients who have failed in prior amphotericin B deoxycholate treatment. With the modification of the lipid structure, Aufulike has altered the metabolism and distribution characteristics of amphotericin B, reducing the incidence of nephrotoxicity and hypokalaemia and providing a safe and effective medication option for patients with invasive fungal disease. Anfulike was included into the NRDL through negotiation in December 2021, improving the drug accessibility and further expanding the patient population who can benefit from this drug.

COPIKTRA (duvelisib capsules) obtained drug registration approval in China in March 2022 for the treatment of adult patients with relapsed or refractory follicular lymphoma after at least two prior systemic therapies. The product is the first approved orally available dual PI3K-δ and PI3K-γ inhibitor worldwide, and is also the first approved PI3K selective inhibitor in China.